161 related articles for article (PubMed ID: 11385958)
21. Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting.
Pavlinkova G; Batra SK; Colcher D; Booth BJ; Baranowska-Kortylewicz J
Peptides; 2003 Mar; 24(3):353-62. PubMed ID: 12732332
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Rogers BE; Roberson PL; Shen S; Khazaeli MB; Carpenter M; Yokoyama S; Brechbiel MW; LoBuglio AF; Buchsbaum DJ
Cancer Biother Radiopharm; 2005 Oct; 20(5):502-13. PubMed ID: 16248766
[TBL] [Abstract][Full Text] [Related]
23. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
[TBL] [Abstract][Full Text] [Related]
24. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.
Huls GA; Heijnen IA; Cuomo ME; Koningsberger JC; Wiegman L; Boel E; van der Vuurst de Vries AR; Loyson SA; Helfrich W; van Berge Henegouwen GP; van Meijer M; de Kruif J; Logtenberg T
Nat Biotechnol; 1999 Mar; 17(3):276-81. PubMed ID: 10096296
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct.
Pavlinkova G; Booth BJ; Batra SK; Colcher D
Clin Cancer Res; 1999 Sep; 5(9):2613-9. PubMed ID: 10499640
[TBL] [Abstract][Full Text] [Related]
26. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
27. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
[TBL] [Abstract][Full Text] [Related]
28. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
[TBL] [Abstract][Full Text] [Related]
29. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody.
Zhang M; Yao Z; Saga T; Sakahara H; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1998 Jan; 39(1):30-3. PubMed ID: 9443734
[TBL] [Abstract][Full Text] [Related]
30. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
Weiden PL
Leuk Lymphoma; 2002 Oct; 43(10):1971-3. PubMed ID: 12481894
[TBL] [Abstract][Full Text] [Related]
31. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
32. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy.
Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA
Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462
[TBL] [Abstract][Full Text] [Related]
33. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
34. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
35. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
36. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion.
Kipriyanov SM; Little M; Kropshofer H; Breitling F; Gotter S; Dübel S
Protein Eng; 1996 Feb; 9(2):203-11. PubMed ID: 9005442
[TBL] [Abstract][Full Text] [Related]
37. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
38. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
39. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
40. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
